Document:

EX-10.9

 Exhibit 10.9 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 

LICENSE AGREEMENT 
 This
License Agreement (this “Agreement”) is made and is effective this 21th day of June, 2017 (the “Effective Date”) between TCR2 Therapeutics, Inc., a Delaware
corporation (“TCR2”) and having an address at 450 Kendall St, Cambridge, MA 02142, and Harpoon Therapeutics, Inc., a Delaware corporation (“HARPOON”) and having an address at Suite 250, 4000 Shoreline Ct., South San
Francisco, CA 94080. TCR2 and HARPOON are each referred to as a “Party” and collectively referred to as the “Parties.” 

Recitals 
 WHEREAS,
TCR2 and HARPOON are engaged in the research and development of therapeutics for the treatment of diseases; 
 WHEREAS, each Party
possesses certain technology and related intellectual property rights useful for the research, development, and commercialization of therapeutics for the treatment of diseases; 

WHEREAS, TCR2 granted to HARPOON certain rights under the Material Transfer Agreement dated August 7, 2016 (the “BCMA
MTA”); 
 WHEREAS, HARPOON granted to TCR2 certain rights under the Material Transfer Agreement dated October 28, 2016 (the
“Mesothelin MTA”); 
 WHEREAS, TCR2 wishes to grant to HARPOON, a perpetual, irrevocable,
non-exclusive, worldwide, royalty-free, fully paid up license under the Licensed TCR2 Patent Rights (as defined below) to develop, make, have made, use, import, export, offer for sale or sell or otherwise
commercialize Products (as defined below) with the right to sublicense, in all cases subject to the terms and conditions of this Agreement; 

WHEREAS, HARPOON wishes to grant to TCR2, a perpetual, irrevocable, non-exclusive, worldwide,
royalty-free, fully paid up license under the Licensed HARPOON Patent Rights (as defined below) to develop, make, have made, use, import, export, offer for sale or sell or otherwise commercialize Products (as defined below) with the right to
sublicense, in all cases subject to the terms and conditions of this Agreement; 
 NOW THEREFORE, TCR2 and HARPOON, intending to be
legally bound, agree as follows: 
 ARTICLE 1 

Definitions 

1.1    “Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is
under common control with such Party. For purposes of this Section 1.1, “control” shall refer to (i) in the case of a Person that is a corporate entity, direct or indirect ownership of more

  
 1 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

than fifty percent (50%) of the stock or shares having the right to vote for the election of directors of such Person and (ii) in the case of a Person
that is not a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise. 

1.2    “Base BCMA Binder” means the BCMA antibody sequence set forth on Exhibit A. 

1.3    “Base MSLN Binders” means the MSLN antibody sequences set forth on Exhibit B. 

1.4    “Base Binders” means either Base BCMA Binder or Base MSLN Binders. 

1.5    “Confidential Information” means any confidential or proprietary information furnished by one
Party to the other Party in connection with this Agreement, provided that such information is (i) specifically designated as confidential or (ii) reasonably identifiable by an individual familiar with the industry as
confidential or proprietary. Confidential Information includes: 

(a)    non-public information disclosed by either Party to the other Party in the
initial and any subsequent Regulatory Base Binder Reports pursuant to Section 3.3; 
 (b)    the know how
set forth on Exhibit E that is disclosed or made available by HARPOON to TCR2 pursuant to the grant of a know how license under Section 2.1(iii); and 

(c)    information of one Party received by the other Party prior to the Effective Date pursuant to the Confidentiality
Agreement between the Parties, dated as of September 1, 2015, the BCMA MTA and the Mesothelin MTA. 

1.6    “Controlled” means, with respect to Patent Rights, that a Party owns or has a license or
sublicense to such Patent Rights and has the ability to grant a license or sublicense to such Patent Rights as provided for in this Agreement, or has the ability to assign its right, title and interest in and to such Patent Rights, without violating
the terms of any agreement or other arrangement with any Third Party. 
 1.7    “Cover,”
“Covering” or “Covered” means, with respect to a product, technology, process or method, that in the absence of ownership of or a license granted under Licensed Patent Rights, the manufacture, use, offer for sale,
sale, exportation or importation of such product or the practice of such technology, process or method would infringe such Licensed Patent Rights. 

1.8    “HARPOON Improved BCMA Binders” means the BCMA antibody sequences derived from, or improvements
to, the Base BCMA Binder that may have been generated, developed or invented by or on behalf of HARPOON prior to the Effective Date, or are generated, developed or invented by or on behalf of HARPOON on and after the Effective Date

  
 -2- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

pursuant to Section 3.2. Such derivations and improvements may include, but are not limited to, humanization, affinity enhancement, and cross
reactivity optimization. 
 1.9    “Improved Binders” means any and all of HARPOON Improved BCMA
Binders, and TCR2 Improved MSLN Binders (as defined below). 
 1.10    “IND” means an investigational
new drug application filed by either Party with the FDA, or the equivalent application in any foreign jurisdiction filed with another Regulatory Authority. 

1.11    “Intellectual Property” means ideas, concepts, discoveries, inventions, developments, know-how,
trade secrets, techniques, methodologies, modifications, processes, innovations, improvements, writings, documentation, electronic code, data and rights (whether or not protectable under state, federal or foreign patent, trademark, copyright or
similar laws) or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable. 

1.12    “Law” means all federal, state, provincial, local, supranational, national and regional laws,
statutes, rules, codes, regulations, orders, judgments, ordinances, guidelines, directives and regulatory requirements applicable to a Party, this Agreement or the activities contemplated hereunder. 

1.13    “Licensed HARPOON Patent Rights” means any patents or patent applications and any and all related
Patent Rights (a) listed on Exhibit D, but only to the extent such patents or patent applications and any and all related Patent Rights Cover the Base MSLN Binders, or (b) to the extent Covering the Base MSLN Binders.
HARPOON shall endeavor to amend and update Exhibit D to incorporate the details of any additional Licensed HARPOON Patent Rights during the Term. 

1.14    “Licensed Patent Rights” means either Licensed TCR2 Patent Rights (as defined below) or Licensed
HARPOON Patent Rights. 
 1.15    “Licensed TCR2 Patent Rights” means any patents or patent
applications and any and all related Patent Rights (a) listed on Exhibit C, but only to the extent such patents or patent applications and any and all related Patent Rights Cover the Base BCMA Binders, or (b) Covering
the Base BCMA Binder. TCR2 shall endeavor to amend and update Exhibit C to incorporate the details of any additional Licensed TCR2 Patent Rights during the Term. 

1.16    “Patent Rights” means with respect to any patents or patent applications, any and all
(a) patents issuing from such patent applications, (b) substitutions, divisionals, renewals, continuations or continuations-in-part (only to the extent of claims that are entitled to
the priority date of the parent application); (c) patents of addition, restorations, extensions, supplementary protection certificates, registration or confirmation patents, patents resulting from post-grant proceedings, re-issues and re-examinations; (d) other patents or patent applications claiming and entitled to claim priority to (i) such patents and patent applications and any patent or patent application specified in (a),
(b) or (c), or (ii) any patent or patent application from which such 

  
 -3- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

patents and patent applications or a patent or patent application specified in (a), (b) or (c) claims and is entitled to claim priority; (d) all
rights of priority attendant to such patents and patent applications and any of the patents and patent applications listed in (a) through (c); and (e) in each case of such patents and patent applications and of the patents and patent
applications described in (a) through (d), including all counterparts and foreign equivalents thereof filed in any country, territory or jurisdiction in the world. 

1.17    “Person” means any natural person or any corporation, company, partnership, joint venture, firm
or other entity, including a Party, or any government or agency or political subdivision thereof. 

1.18    “Product” means, on a
country-by-country basis, any product or part of a product containing either a Base Binder or Improved Binder, the making, using, selling, offering for sale, importing
or exporting of which in such country would, but for the licenses granted herein, infringe any of the Licensed Patent Rights in such country. 

1.19    “Prosecution and Maintenance” or “Prosecute and Maintain” means, with respect to
the applicable Patent Rights, the preparation, filing, prosecution and maintenance of such Patent Rights, as well as re-examinations, reissues, appeals, and requests for patent term adjustments and patent term
extensions with respect to such Patent Rights, together with the initiation or defense of interferences, the initiation or defense of oppositions, post grant review, and other similar proceedings with respect to the particular Patent Rights, and any
appeals therefrom. For clarification, “Prosecution and Maintenance” or “Prosecute and Maintain” shall not include any other enforcement actions taken with respect to Patent Rights. 

1.20    “Regulatory Approval” means, with respect to a country or territory, the approvals (including any
applicable governmental price and reimbursement approvals), licenses, registrations or authorizations of Regulatory Authorities necessary for the commercialization of a pharmaceutical product in such country or territory, including, as applicable,
approval of a BLA or comparable filing in the United States or approval of a comparable filing in any other country or jurisdiction, including a marketing authorization approval by the EMA. 

1.21    “Regulatory Authority” means a federal, national, multinational, state, provincial or local
regulatory agency, department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, export, promotion, marketing or sale of a product in the applicable country. 

1.22    “Regulatory Base Binder Information” means any information related to a Base Binder that a
comparable Third Party in the same industry would reasonably be expected to provide to the Regulatory Authority in order to file an IND and/or seek Regulatory Approval for the Product containing such Base Binder. 

1.23    “Sublicensee” shall have the meaning set forth in Section 2.2(a). 

1.24    “TCR2 Improved MSLN Binders” means the MSLN antibody sequences derived from, or improvements to,
the Base MSLN Binders that may have been generated, 

  
 -4- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

developed or invented by or on behalf of TCR2 prior to the Effective Date, or are generated, developed or invented by or on behalf of TCR2 on and after the
Effective Date pursuant to Section 3.2. Such derivations and improvements may include, but are not limited to, humanization, affinity enhancement, and cross reactivity optimization. 

1.25    “Term” means the term of this Agreement as provided in Section 9.1. 

1.26    “Third Party” means any Person other than a Party or any of its Affiliates. 

1.27    Additional Definitions. Each of the following definitions is set forth in the section of this Agreement
indicated below: 
  

			
	 Definition
	 	 Section

	AAA	 	10.11(b)(i)
	 Bankruptcy Code
 HARPOON Intellectual
Property
	 	 2.5(a)
 5.1

	Prosecuting Party	 	5.2(b)
	TCR2 Intellectual Property	 	5.1

 ARTICLE 2 

Grant of License 

2.1    License Grant. 

Subject to the terms and conditions of this Agreement, without additional consideration, (i) TCR2 hereby grants to HARPOON a perpetual,
irrevocable, non-exclusive, worldwide, royalty-free, fully paid up license under the Licensed TCR2 Patent Rights, with the right to grant sublicenses as set forth in Section 2.2, to research, develop, make, have made, use, sell, have
sold, offer to sell, import, export, commercialize or otherwise exploit Products containing the Base BCMA Binder, itself and through its Affiliates and Third Parties; (ii) HARPOON hereby grants to TCR2 a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid up license under the Licensed HARPOON Patent Rights, with the right to grant sublicenses as set forth in Section 2.2, to research, develop, make, have
made, use, sell, have sold, offer to sell, import, export, commercialize or otherwise exploit Products containing Base MSLN Binders, itself and through its Affiliates and Third Parties; and (iii) HARPOON hereby grants to TCR2 a
perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid up, non-exclusive license, with the right to grant sublicenses as set forth in
Section 2.2, to use the know-how that is set forth on Exhibit E hereto. For the avoidance of doubt, HARPOON does not grant to TCR2 any rights or licenses whatsoever with respect to any HARPOON
Improved BCMA Binders or Products containing the Base BCMA Binder or any HARPOON Improved 

  
 -5- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

BCMA Binders, and HARPOON shall not update Exhibit E (such that the know how that is being licensed by HARPOON to TCR2 hereunder, is limited to the know how
that is set forth on Exhibit E as of the Effective Date). It is understood and agreed that TCR2 shall not use the know-how that is licensed hereunder in any way that would preclude or prevent HARPOON from
being able to use any of the licensed know how without restriction, or that would otherwise impair HARPOON’s ability to use any of the licensed know-how without restriction. 

2.2    Sublicensing. 

(a)    Each Party shall have the right to grant sublicenses under the license granted to it under Section 2.1
hereof (a “Sublicensee”); provided that each such sublicense shall be subject to all relevant provisions, restrictions and limitations set forth in this Agreement. Each Party shall be responsible for each of its
Sublicensee’s complying with all obligations of such Party under this Agreement that are applicable to sublicenses. 

(b)    If this Agreement is terminated for any reason, then, at the option of any Sublicensee not in default of the
applicable sublicense (or any provision of this Agreement applicable to such Sublicensee), it shall become a direct licensee under, and subject to the terms and conditions of, this Agreement, subject only to modifications with respect to territory,
field and exclusivity (as applicable) so as to accommodate all such Sublicensees. 
 2.3    Affiliates and
Sublicensees. Each Party may exercise or perform, or have exercised or performed on its behalf, some or all of its rights or obligations under this Agreement by one or more of such Party’s Affiliates or Sublicensees. Each Party shall be
responsible for each of its Affiliates’ and Sublicensees’ compliance with all obligations of such Party under this Agreement. 

2.4    Subcontractors. Each Party may exercise or perform some or all of its rights or obligations under this
Agreement by subcontracting the exercise or performance of all or any portion of such rights and obligations on the Party’s behalf, provided that the Party shall be responsible for each of its subcontractors complying with all obligations of
the Party under this Agreement. 
 2.5    Section 365(n) of the Bankruptcy Code. 

(a)    All rights and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed
to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended or any comparable Law outside the United States (the “Bankruptcy Code”), licenses of rights to “intellectual
property” as defined in Section 101(35A) of the Bankruptcy Code. Each Party agrees that each Party, as a party to this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any
other provisions of Law outside the United States that provide similar protection for “intellectual property.” Any agreement supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of
Section 365(n) of the Bankruptcy Code. 

  
 -6- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

(b)    In the event that either Party is unable to obtain or retain the licenses set forth in Section 2.1 of
this Agreement as a result of a bankruptcy proceeding by or against the other Party under provisions of applicable Law analogous to Section 365(n) of the Bankruptcy Code, such Party shall have a right to purchase such other Party’s
right, title and interest in and to Licensed Patent Rights of such other Party at fair market value, provided that such Party gives such other Party written notice of such intention no later than four (4) weeks after such Party becomes
aware of the commencement of such bankruptcy proceeding. The fair market value of the Licensed Patent Rights shall be determined by an assessment made by a mutually agreed upon third party, or, if the Parties do not agree within thirty
(30) days of such Party’s written notice, a third party reasonably selected by such Party with a background in conducting such assessments. The costs of any such assessment shall be borne equally by the Parties. 

ARTICLE 3 
 Development
and Commercialization 
 3.1    Compliance. Each Party shall, and shall ensure that its Affiliates and
Sublicensees, and its and their subcontractors, conduct all research and development, manufacture and commercialization of Base Binders, Improved Binders, and Products Covered under Licensed Patent Rights in compliance with all Laws. 

3.2    Research and Development Activities. TCR2 may at its sole discretion and expense, and without restriction,
carry out research and development activities on Base MSLN Binders and Improved MSLN Binders during the Term and thereafter. HARPOON may at its sole discretion and expense, and without restriction, carry out research and development activities on
the Base BCMA Binder and Improved BCMA Binders during the Term and thereafter. For the avoidance of doubt, any and all Intellectual Property (and all associated Patent Rights) arising from, made or developed solely by or on behalf of the Party
carrying out such research and development activities (“Developed IP” ) shall also be solely owned by such Party. 

3.3    Regulatory Base Binder Information. Each Party shall provide, within twenty (20) days of receipt of written
request from the other Party made anytime during the Term, a written report of Regulatory Base Binder Information on the Base Binder(s) Covered under the Licensed Patent Rights of such Party. 

ARTICLE 4 
 Consideration

 The Parties jointly and severally represent, warrant and covenant that each has received full and sufficient consideration for all grants made and
obligations undertaken under this Agreement. 
 ARTICLE 5 

Intellectual Property Protection and Related Matters 

5.1    Ownership. 

  
 -7- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

5.1.1    As between the Parties, other than as provided for in this Section 5.1, each Party shall
solely own all Intellectual Property, including Patent Rights related thereto, made, conceived, reduced to practice, or otherwise discovered, whether prior to, on or after the Effective Date, solely by employees, agents, contractors or consultants
of such Party or its Affiliates. For purposes of determining ownership under this Section 5.1, inventorship shall be determined in accordance with the Laws of the United States. 

5.1.2    Notwithstanding the foregoing or anything to the contrary herein, the Parties agree that all Intellectual
Property, including Patent Rights related thereto, made, conceived, reduced to practice, or otherwise discovered, whether prior to, on or after the Effective Date, by or on behalf of a Party or its Affiliates, alone or with others, pertaining to:

 (i)    any and all Base MSLN Binders (either isolated or as incorporated into a composition), 

(ii)    any and all HARPOON Improved BCMA Binders, 

(iii)    any and all products containing HARPOON Improved BCMA Binders or the Base BCMA Binder, which
products are covered by any claims in [***], and 
 (iv)    any and all Products containing HARPOON
Improved BCMA Binders or the Base BCMA Binder, which Products are developed and/or commercialized by or on behalf of HARPOON or its Affiliates or Sublicensees, 

in each case, shall be solely owned by HARPOON (“HARPOON Intellectual Property”). 

5.1.3 Notwithstanding the foregoing or anything to the contrary herein, the Parties agree that all Intellectual Property, including Patent
Rights related thereto, made, conceived, reduced to practice, or otherwise discovered, whether prior to, on or after the Effective Date, by or on behalf of a Party or its Affiliates, alone or with others, pertaining to: 

(i)    any and all Base BCMA Binders (either isolated or as incorporated into a composition), 

(ii)    any and all TCR2 Improved MSLN Binders, 

(iii)    any and all products containing TCR2 Improved MSLN binders or Base MSLN Binders, which products
are covered by any claims in [***], and 
 (iv)    any and all Products containing TCR2 Improved MSLN
Binders or Base MSLN Binders, which Products are developed and/or commercialized by or on behalf of TCR2 or its Affiliates or Sublicensees. 
 in each case,
shall be solely owned by TCR2 (“TCR2 Intellectual Property”). 

  
 -8- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

5.1.4    Accordingly and without additional consideration, (i) TCR2 hereby assigns and agrees to assign to Harpoon,
all HARPOON Intellectual Property, including Patent Rights related thereto and enforcement rights, made, conceived, reduced to practice, or otherwise discovered, whether prior to, on or after the Effective Date, and TCR2 shall cause its employees,
agents, contractors and Affiliates to do the same; and (ii) HARPOON hereby assigns and agrees to assign to TCR2, all TCR2 Intellectual Property, including Patent Rights related thereto and enforcement rights, made, conceived, reduced to
practice, or otherwise discovered, whether prior to, on or after the Effective Date, and HARPOON shall cause its employees, agents, contractors and Affiliates to do the same. For the avoidance of any doubt, under no circumstances and in no event,
under this Agreement or otherwise, shall TCR2 acquire any ownership rights in any Base MSLN Binder, nor shall HARPOON acquire any ownership rights in the Base BCMA Binder. 

5.2    Prosecution and Maintenance of Licensed Patent Rights. 

(a)    During the Term and thereafter, HARPOON shall remain solely responsible for the Prosecution and Maintenance of all
HARPOON Intellectual Property worldwide and TCR2 shall remain solely responsible for the Prosecution and Maintenance of all TCR2 Intellectual Property worldwide. 

(b)    The Party controlling the Prosecution and Maintenance of the applicable Licensed Patent Rights in accordance with
Section 5.2(a) is referred to as the “Prosecuting Party”. The Prosecuting Party shall be responsible for all fees and costs charged by patent counsel with respect to the Prosecution and Maintenance of the applicable
Licensed Patent Rights and all other out-of-pocket costs and expenses incurred by the Prosecuting Party in connection with such Prosecution and Maintenance of the
applicable Licensed Patent Rights during the Term. For clarity, such expenses shall not include any actions undertaken by the other Party other than at the Prosecuting Party’s request. 

5.3    Third Party Infringement. 

Each Party shall notify the other Party promptly of any knowledge it acquires of any actual or potential infringements of the Licensed Patent
Rights with respect to any activities of a Third Party in any country in the world and shall provide the other Party with all available evidence regarding such known or suspected infringement or unauthorized use. 

ARTICLE 6 

Confidentiality 

6.1    Confidential Obligations. Each Party shall (a) maintain in strict confidence the Confidential
Information of the other Party to the same extent such Party maintains its own confidential information, but in no event less than a reasonable degree of care, (b) not disclose such Confidential Information to any Third Party without the
prior written consent of the other Party (except as permitted pursuant to Section 6.3 below), and (c) not use such Confidential Information for any purpose except those expressly permitted by this Agreement. The obligations
of confidentiality, non-disclosure and non-use under this Section 6.1 shall be in full 

  
 -9- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

force during the Term and for a period of ten (10) years thereafter. Each Party, upon the request of the other Party, will return all copies of or destroy
(and certify such destruction in writing) the Confidential Information disclosed or transferred to it by the other Party pursuant to this Agreement, within sixty (60) days of such request or, if earlier, the termination or expiration of
this Agreement; provided however that a Party may retain (i) Confidential Information of the other Party which expressly survives such termination pursuant to this Agreement, and (ii) one (1) copy of all other Confidential
Information in archives solely for the purpose of establishing the contents thereof; provided, further, that a Party is not required to return or destroy Confidential Information contained in electronic back-ups unless and until such Confidential
Information is accessed. 
 6.2    Exceptions to Confidentiality. Notwithstanding the foregoing, the obligations
of confidentiality set forth in Section 6.1 shall not apply to information that, in each case as demonstrated by competent written documentation: 

(a)    is publicly disclosed or made generally available to the public by the disclosing Party, either before or after it
becomes known to the receiving Party; 
 (b)    was known to the receiving Party, without any obligation to keep it
confidential, prior to the date of first disclosure by the disclosing Party to the receiving Party, as shown by the receiving Party’s files and records; 

(c)    is subsequently disclosed to the receiving Party by a Third Party lawfully in possession thereof without obligation
to keep it confidential and without a breach of such Third Party’s obligations of confidentiality; 
 (d)    has
been publicly disclosed or made generally available to the public other than through any act or omission of the receiving Party or its Affiliates or Sublicensees in breach of this Agreement; or 

(e)    has been independently developed by the receiving Party without the aid, application or use of or reliance on or
reference to the disclosing Party’s Confidential Information (the competent written proof of which must be contemporaneous with such independent development). 

6.3    Authorized Disclosure. Notwithstanding Section 6.1, a Party may disclose Confidential
Information of the other Party to the extent such disclosure is reasonably necessary in the following instances: 

(a)    complying with applicable Laws or submitting information to governmental authorities; provided that if a
Party is required by Law or governmental authority to make any public disclosure of Confidential Information of the other Party, to the extent it may legally do so, it will give reasonable advance written notice to the other Party of such disclosure
and will use its reasonable efforts to challenge or limit such required disclosure or secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise); 

  
 -10- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

(b)    to obtain and maintain Regulatory Approval of Products or to research, develop, make, have made, use, have used,
offer to sell, sell, import, export, commercialize or otherwise exploit Products subject to and in accordance with this Agreement; 

(c)    to its Affiliates, its and their directors, and to prospective and actual acquirers, lenders, licensees, investors
and sublicensees, and to each of their employees, consultants, contractors, agents, accountants, lawyers, advisors, investors and underwriters, on a need to know basis, each of whom, in the case of Third Parties, prior to disclosure must be bound by
written or professional ethical obligations of confidentiality and non-use equivalent in scope to those set forth in this Article 6; or 

(d)    to the extent mutually agreed to in writing by the Parties. 

ARTICLE 7 

Representations and Lack of Warranties 

7.1    Representations of Authority. Each Party represents and warrants to the other that as of the Effective Date
it has full right, power and authority to enter into this Agreement and to perform its respective obligations under this Agreement. 

7.2    Consents. Each Party represents and warrants that as of the Effective Date all necessary consents, approvals
and authorizations of all government authorities and other Persons required to be obtained by such Party in connection with execution, delivery and performance of this Agreement have been obtained. 

7.3    No Conflict. Each Party represents and warrants that, as of the Effective Date, the execution and delivery
of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable Laws and (b) do not conflict with, violate or breach or constitute a default of, or
require any consent under, any contractual obligations of such Party, except such consents as have been obtained as of the Effective Date. 

7.4    Employee, Consultant and Advisor Obligations. Each Party represents and warrants that, as of the Effective
Date, each of its and its Affiliates’ employees, consultants and advisors has executed an agreement or has an existing obligation under law obligating such employee, consultant or advisor to maintain the confidentiality of Confidential
Information to the extent required under Article 6. 
 7.5    No Warranties. EXCEPT AS OTHERWISE
EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THERE ARE NO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY. EACH PARTY MAKES NO WARRANTIES, EXPRESS OR
IMPLIED, 

  
 -11- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

REGARDING THE PATENTABILITY, VALIDITY OR ENFORCEABILITY OF ANY LICENSED PATENT RIGHTS. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND
WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 
 ARTICLE 8 

Indemnification; Limitation on Damages 

8.1    By HARPOON. HARPOON agrees to defend TCR2, its Affiliates and their respective directors, officers,
employees, consultants and agents at HARPOON’s cost and expense, and shall indemnify and hold harmless TCR2 and its Affiliates and their respective directors, officers, employees, consultants and agents from and against any liabilities, losses,
costs, damages, fees or expenses (including without limitation, attorney fees and the costs of litigation, investigation and settlement regardless of outcome) arising out of any Third Party claim, suit, action or demand to the extent resulting from
(i) any breach by HARPOON of any of its representations, warranties or obligations pursuant to this Agreement, (ii) the alleged or actual infringement or misappropriation of any Third Party Intellectual Property by the manufacture,
use or sale of the Base BCMA Binder, any HARPOON Improved BCMA Binder, or Product containing the Base BCMA Binder or HARPOON Improved BCMA Binder, in each case by or on behalf of HARPOON or its Affiliates or Sublicensees, (iii) personal
or bodily injury, illness or death, property damage or other loss or damage resulting from the research, development, making, having made, using, offering for sale, selling, having sold, importing, exporting, commercialization or other exploitation
of Products containing the Base BCMA Binder or any HARPOON Improved BCMA Binder, in each case by or on behalf of HARPOON or its Affiliates or Sublicensees. 

8.2    By TCR2. TCR2 agrees to defend HARPOON, its Affiliates and their respective directors, officers, employees,
consultants and agents at TCR2’s cost and expense, and shall indemnify and hold harmless HARPOON and its Affiliates and their respective directors, officers, employees, consultants and agents from and against any liabilities, losses, costs,
damages, fees or expenses (including without limitation, attorney fees and the costs of litigation, investigation and settlement regardless of outcome) arising out of any Third Party claim, suit, action or demand to the extent resulting from
(i) any breach by TCR2 of any of its representations, warranties or obligations pursuant to this Agreement, (ii) the alleged or actual infringement or misappropriation of any Third Party Intellectual Property by the manufacture, use or
sale of any Base MSLN Binder, TCR2 Improved MSLN Binder, or Product containing a Base MSLN Binder or TCR2 Improved MSLN Binder, in each case by or on behalf of TCR2 or its Affiliates or Sublicensees, (iii) personal or bodily injury, illness or
death, property damage or other loss or damage resulting from the research, development, making, having made, using, offering for sale, selling, having sold, importing, exporting, commercialization or other exploitation of Products containing Base
MSLN Binders or TCR2 Improved MSLN Binders, in each case by or on behalf of TCR2 or its Affiliates or Sublicensees. 

  
 -12- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

8.3    Procedures. A Person entitled to indemnification under this Article 8 (an “Indemnified
Party”) shall give prompt written notification to the Party from whom indemnification is sought (the “Indemnifying Party”) of any claim, suit, action or demand for which indemnification is sought under this Agreement;
provided, however, that no delay or failure on the part of an Indemnified Party in so notifying the Indemnifying Party shall relieve the Indemnifying Party of any liability or obligation hereunder except to the extent of any damage or liability
caused by or arising out of such delay or failure. Within thirty (30) days after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense and settlement of such
claim, suit, action or demand with counsel reasonably satisfactory to the Indemnified Party. If the Indemnifying Party does not assume control of such defense, the Indemnified Party shall control such defense. The Party not controlling such defense
may participate therein with counsel of its own choosing at its own expense; provided that, the Indemnified Party shall have the right to retain its own counsel, at the expense of the Indemnifying Party, if representation of such Indemnified
Party by the counsel retained by the Indemnifying Party would be inappropriate because of actual or potential differences in the interests of such Indemnified Party and any other party represented by such counsel. The Indemnified Party shall
cooperate with the Indemnifying Party in its defense and settlement of any claim, suit, action or demand for which indemnification is sought under this Agreement, and the Indemnified Party shall not agree to any disposition, compromise or settlement
of such action, suit, proceeding or claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. 

8.4    NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE
DAMAGES, INCLUDING LOST PROFITS OR LOSS OF USE, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH LOSSES OR DAMAGES OR IF A PARTY KNEW OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES. THIS EXCLUSION OF
LOSSES AND DAMAGES SHALL NOT APPLY WITH RESPECT TO A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTIONS 8.1 AND 8.2. 
 ARTICLE 9

 Term and Termination 

9.1    Term. This Agreement shall become effective as of the Effective Date and unless earlier terminated as set
forth in this Article 9, shall otherwise remain in effect on a Product-by- Product basis until it expires (the “Term”) in its entirety upon the
expiration of all Licensed Patent Rights. 
 9.2    Termination for Material Breach. Upon any material breach of
this Agreement by either Party, the other Party may terminate this Agreement by providing sixty (60) days’ prior written notice to the breaching Party, specifying the material breach. The termination shall become effective at the end of
the sixty (60) day period unless the breaching Party cures such breach during such sixty (60) day period. 

  
 -13- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

9.3    Termination for Bankruptcy. To the extent allowed under applicable Law, either Party shall have the right to
terminate this Agreement in the event of the commencement of any proceeding in or for bankruptcy, insolvency, dissolution or winding up by or against the other Party (other than pursuant to a corporate restructuring) that is not dismissed or
otherwise disposed of within sixty (60) days thereafter and/or the administrator of the bankruptcy estate or the Party under in-court restructuring has not, within five (5) days after the receipt of an inquiry from the other Party,
confirmed that the bankruptcy estate or the Party under in-court restructuring will adopt this Agreement. 

9.4    Effects of Termination. 

(a)    Generally. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing
prior to such expiration or termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination.
Termination of this Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this
Agreement, regardless of whether or not such breach was the reason for the termination. 
 (b)    Rights and Licenses.
In the event of any termination of this Agreement by a Party pursuant to Section 9.2 or 9.3, notwithstanding anything contained in this Agreement to the contrary, upon the effective date of such termination: (i) all rights and
licenses granted herein to the terminated Party shall automatically terminate and all such rights and licenses granted by the terminating Party to the terminated Party shall revert in their entirety to the terminating Party; and (ii) the
terminated Party shall return or destroy all Confidential Information of the terminating Party. 

9.5    Survival. The following provisions shall survive the expiration or termination of this Agreement: Article
1 (Definitions) (to the extent necessary to give effect to other surviving provisions), Article 5 (Intellectual Property), Article 6 (Confidentiality), Article 8 (Indemnification; Limitation on Damages) and Article 10
(Miscellaneous Provisions), and Sections 2.2 (Sublicensing) (and such other provisions of this Agreement as are necessary to give effect to the continuing licenses contemplated under Section 2.2), 9.4 (Effects of
Termination) and this Section 9.5 (Survival). 
 ARTICLE 10 

Miscellaneous Provisions 

10.1    Governing Law; Language. This Agreement and all disputes arising out of or related to this Agreement shall
be construed and the respective rights of the Parties determined in accordance with the laws of the State of New York, U.S.A., excluding application of any conflict of laws principles that would require application of the laws of a jurisdiction
outside of New York, and will be subject to the exclusive jurisdiction of the courts of competent jurisdiction 

  
 -14- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

located in New York, New York. The Parties hereby expressly consent to the jurisdiction of such courts and irrevocably waive any objection to jurisdiction or
venue. This Agreement and all communications related to it, or to any dispute or controversy arising out of it, shall be conducted in English. 

10.2    Notice. Any notices required or permitted by this Agreement shall be in writing, shall specifically refer
to this Agreement, and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic mail or registered or certified mail, postage prepaid, return receipt requested, to the following address or
facsimile number of the Parties: 
 If to HARPOON: 

Harpoon Therapeutics, Inc. 

Suite 250 
 4000 Shoreline Ct.,

 South San Francisco, CA 94080 

Attention: Chief Executive Officer 
 If to TCR2:

 TCR2 Therapeutics, Inc. 

450 Kendall St 
 Cambridge, MA
02142 
 Attention: Chief Executive Officer 

All notices under this Agreement shall be deemed effective upon receipt. A party may change its contact information immediately upon written
notice to the other party in the manner provided in this Section 10.2. 

10.3    Assignment. Either Party may assign this Agreement, in its entirety, without the consent of the other
Party, (a) in connection with a sale or transfer of all or substantially all of the business and assets of the assigning Party to which this Agreement relates, including by way of merger, consolidation, transfer, or sale of assets related to
this Agreement or (b) to an Affiliate. Any assignment in circumvention of the foregoing shall be void. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective
permitted successors and assigns. 
 10.4    Entire Agreement. This Agreement constitutes the entire agreement
between the Parties with respect to its subject matter and supersedes all prior agreements or understandings between the Parties relating to its subject matter including the Confidentiality Agreement, the BCMA MTA and the Mesothelin MTA. 

10.5    Interpretation. The captions and headings to this Agreement are for convenience only, and are to be of no
force or effect in construing or interpreting any of the provisions of this 

  
 -15- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

Agreement. Unless specified to the contrary, references to Articles, Sections or Exhibits mean the particular Articles, Sections or Exhibits to this Agreement
and references to this Agreement include all Exhibits hereto. Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words “include” or “including” shall be construed as incorporating, also,
“but not limited to” or “without limitation;” (b) the word “day” or “year” means a calendar day or year unless otherwise specified; (c) the word “notice” shall mean notice in writing
(whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (d) the words “hereof,” “herein,” “hereby” and
derivative or similar words refer to this Agreement (including any Exhibits); (e) the word “or” shall be construed as the inclusive meaning identified with the phrase “and/or;” (f) provisions that require that a Party
or the Parties hereunder “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter or otherwise;
(g) words of any gender include the other gender; (h) words using the singular or plural number also include the plural or singular number, respectively; and (i) the word “law” (or “laws”) when
used herein means any applicable, legally binding statute, ordinance, resolution, regulation, code, guideline, rule, order, decree, judgment, injunction, mandate or other legally binding requirement of a government entity, together with any
then-current modification, amendment and re-enactment thereof, and any legislative provision substituted therefor. The Parties and their respective counsel have had an opportunity to fully negotiate this Agreement. If any ambiguity or question of
intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this
Agreement. No prior draft of this Agreement shall be used in the interpretation or construction of this Agreement. 

10.6    Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified only by means of a
written instrument signed by both Parties. Any waiver of any right or failure to act in a specific instance shall related only to such instance and shall not be construed as an agreement to waive any right or fail to act in any other instance,
whether or not similar. 
 10.7    Severability. In the event that any provision of this Agreement shall be held
invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any other provision of this Agreement. The Parties shall consult one another and use reasonable efforts to agree upon a valid and enforceable provision
that is a reasonable substitute for the invalid or unenforceable provision. 
 10.8    Use of Name. Neither Party
shall use the other Party’s name (except in connection with disclosures permitted under Article 6) or logo without the other Party’s express prior written consent, which consent may be granted in the context of the Parties mutually
approving in writing a press release or other public disclosure related to this Agreement. 

10.9    Counterparts. This Agreement may be executed in counterparts, each of which counterparts, when so executed
and delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument. 

  
 -16- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

10.10    Force Majeure. Neither Party will be responsible for delays (excluding delays in payment) resulting from
causes beyond the reasonable control of such Party, including without limitation, fire, explosion, flood, war, strike, or riot, provided that the nonperforming Party promptly notifies the other Party in writing of such causes and uses
commercially reasonable efforts for a company of its size and resources to avoid or promptly remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are removed. 

10.11    Dispute Resolution. 

(a)    Escalation. If any dispute arises out of or relates to this Agreement, the Parties agree to first seek to
resolve such dispute by referring such dispute to the respective Chief Executive Officers of each Party for resolution. Such referral shall take place within thirty (30) days after a written request by either Party to the other Party that
resolution by the Chief Executive Officers be attempted. If, after an additional sixty (60) days, the Chief Executive Officers of the Parties have not succeeded in negotiating a resolution of the dispute, and a Party wishes to pursue the
matter, such Party may initiate binding arbitration in accordance with Section 10.11(b). 
 (b)    Alternative
Dispute Resolution. Any dispute arising out of or relating to this Agreement that has not been resolved pursuant to Section 10.11(a) shall be resolved through binding arbitration as follows: 

(i)    A Party may submit such dispute to arbitration by notifying the other Party, in writing, of such
dispute. Within thirty (30) days after receipt of such notice, the Parties shall designate in writing a single arbitrator to resolve the dispute; provided, however, that if the Parties cannot agree on an arbitrator within such 30-day period,
the arbitrator shall be selected by the New York, New York office of the American Arbitration Association (the “AAA”). The arbitrator shall not be an Affiliate, employee, consultant, officer, director or stockholder of any Party.

 (ii)    Within thirty (30) days after the designation of the arbitrator, the arbitrator and the
Parties shall meet, at which time the Parties shall be required to set forth in writing all disputed issues and a proposed ruling on the merits of each such issue. 

(iii)    The arbitrator shall set a date for a hearing, which shall be no later than forty-five
(45) days after the submission of written proposals pursuant to Section 10.11(b)(ii), to discuss each of the issues identified by the Parties. The Parties shall have the right to be represented by counsel. Except as provided herein,
the arbitration shall be governed by the Commercial Arbitration Rules of the AAA; provided, however, that the Federal Rules of Evidence shall apply with regard to the admissibility of evidence and the arbitration shall be conducted by a
single arbitrator. 
 (iv)    The arbitrator shall use his or her best efforts to rule on each disputed
issue within thirty (30) days after the completion of the hearings described in Section 10.11(b)(iii). The determination of the arbitrator as to the resolution of any 

  
 -17- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

dispute shall be binding and conclusive upon all Parties. All rulings of the arbitrator shall be in writing and shall be delivered to the
Parties. 
 (v)    The attorneys’ fees of the Parties in any arbitration, fees of the arbitrator,
and costs and expenses of the arbitration shall be borne by the Parties as determined by the arbitrator. 

(vi)    Any arbitration pursuant to this Section 10.11 shall be conducted in New York, New
York, U.S.A. and the arbitrator shall the laws of the State of New York. Any arbitration award may be entered in and enforced by any court of competent jurisdiction. 

(c)    No Limitation. Nothing in this Section 10.11 shall be construed as limiting in any way the right
of a Party to seek an injunction or other equitable relief with respect to any actual or threatened breach of this Agreement without having to prove actual damages or post a bond, or to bring an action in aid of arbitration. Should any Party seek an
injunction or other equitable relief, or bring an action in aid of arbitration, then for purposes of determining whether to grant such injunction or other equitable relief, or whether to issue any order in aid of arbitration, the dispute underlying
the request for such injunction or other equitable relief, or action in aid of arbitration, may be heard by the court in which such action or proceeding is brought. 

10.12    No Third Party Beneficiaries. No Person other than HARPOON, TCR2 and their respective Affiliates,
successors and permitted assignees hereunder, shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement. 

10.13    Independent Contractors. It is expressly agreed that HARPOON and TCR2 shall be independent contractors and
that the relationship between HARPOON and TCR2 shall not constitute a partnership, joint venture or agency. Neither HARPOON nor TCR2 shall have the authority to make any statements, representations, or commitments of any kind, or to take any action,
which shall be binding on the other Party, without the prior written consent of such other Party. 
 10.14    No
Implied Rights or Licenses. Other than as expressly provided for in this Agreement, there are no licenses, rights or interests in or to the Patent Rights or other Intellectual Property or Confidential Information of a Party granted or implied
under this Agreement. 
 [remainder of page intentionally left blank] 

  
 -18- 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. 

 

									
	HARPOON THERAPEUTICS, INC.	 		 	TCR2 THERAPEUTICS, INC.
					
	By:	 	/s/ William E. Picht Jr.	 		 	By:	 	/s/ Garry E. Menzel
	Name:	 	William E. Picht Jr.	 		 	Name:	 	Garry E. Menzel
	Title:	 	Chief Financial Officer	 		 	Title:	 	Chief Executive Officer

  
 19 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

Exhibit A 
 Base BCMA
Binder Sequence 
 [***] 

  
 C-1 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

Exhibit B 
 Base MSLN
Binders Sequences 
 [***] 

  
 D-1 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

Exhibit C 
 Licensed TCR2
Patent Rights 
 [***] 

  
 D-1 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

Exhibit D 
 Licensed
HARPOON Patent Rights 
 [***] 

  
 D-1 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL 

TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED 
  

Exhibit E 
 Licensed Know
How 
 [***] 

  
 D-1EX-10.10

 Exhibit 10.10 

TCR2, INC. 
 CONSULTING
AGREEMENT 
 THIS CONSULTING AGREEMENT (the “Agreement”), made this first day of October, 2015, is entered into by TCR2, Inc.,
a Delaware corporation (the “Company”), and Patrick Baeuerle (the “Consultant”). 
 INTRODUCTION 

The Company desires to retain the services of the Consultant and the Consultant desires to perform certain services for the Company. In
consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows: 

1. Services. 
 1.1
During the Consultation Period (as defined herein), the Consultant agrees to perform such consulting, advisory and related services to and for the Company as may be reasonably requested from time to time by the Company (the “Services”).
Consultant agrees that the Company may, at its discretion, publicize the fact that Consultant is providing Services to the Company by featuring his biography on the Company’s website (if any) and in marketing material relating to the Company
and/or its affiliates. During the time Consultant is providing Services, he will hold the title of “President” of the Company. 

1.2 The Company acknowledges that the Consultant is concurrently providing consulting services for MPM Asset Management LLC (“MPM”)
and for Harpoon Therapeutics, Inc. (“Harpoon”), separate and apart from his Services to the Company. It is understood and agreed that Consultant’s Services under this Agreement will be consistent with Consultant’s obligations to
MPM and to Harpoon; provided, however, that Consultant shall use his reasonable best efforts and all due diligence in performing the Services. 

2. Compensation. 

2.1 Consulting Fees. The consideration described below in this Section 2.1 constitutes the full consideration for the consulting
services to be provided by the Consultant to the Company. 
 (a) The Company shall pay to the Consultant consulting fees of Euros 15,416.66
per month (annualized to Euro 185,000, gross sum), payable in Euros monthly on the last day of each month. Payment for any partial month shall be prorated. Consultant shall also be eligible, at the discretion of the Board of Directors, for an annual
bonus equal to up to 33% of the annual fees paid hereunder, based on Consultant’s performance and the Company’s performance, pro-rated as necessary for the period of time over which Consultant
provides the Services. 

 2.2 Reimbursement of Expenses. The Company shall reimburse the Consultant for all
reasonable and necessary expenses incurred or paid by the Consultant in connection with, or related to, the performance of his services under this Agreement. The Consultant shall submit to the Company itemized monthly statements, in a form
satisfactory to the Company, of such expenses incurred in the previous month. The Company shall pay to the Consultant amounts shown on each such statement within 30 days after receipt thereof. Notwithstanding the foregoing, the Consultant shall not
incur total expenses in excess of US$1,000 per month without the prior written approval of the Company. 
 2.3 Benefits. The Consultant shall
not be entitled to any benefits, coverages or privileges, including, without limitation, social security, unemployment, medical or pension payments, made available to employees of the Company. 

3. Term and Termination. 

3.1 This Agreement shall commence upon the date hereof (the “Effective Date”) and shall continue until the first anniversary of the
Effective Date, after which it shall automatically extend for additional one-year periods (such period, as it may be extended, being referred to as the “Consultation Period”) by mutual consent of the
Parties, and unless sooner terminated in accordance with the provisions of Section 3.2. 
 3.2 Without limiting any rights which
either party to this Agreement may have by reason of any default by the other party (which shall include the right to terminate this Agreement for Cause (as defined herein) as well as any other remedies that may be available at law or in equity),
each party reserves the right to terminate this Agreement at its convenience by written notice given to the other party. Such termination shall be effective upon the date not earlier than 30 days following the date of such notice as shall be
specified in said notice. 
 3.3 Sections 3 through 15 hereof shall survive termination or expiration of this Agreement, unless otherwise
explicitly provided herein. In addition, termination of this Agreement shall not affect the Company’s obligation to pay for services previously performed by the Consultant or expenses reasonably incurred by the Consultant for which the
Consultant is entitled to reimbursement under Section 2.2, above. 
 4. Cooperation. The Consultant shall use his
best efforts in the performance of his obligations under this Agreement. The Company shall provide such access to its information and property as may be reasonably required in order to permit the Consultant to perform his obligations hereunder. The
Consultant shall cooperate with the Company’s personnel, shall not interfere with the conduct of the Company’s business and shall observe all rules, regulations and security requirements of the Company concerning the safety of persons and
property. 
 5. Non-Competition. During the Consultation Period, the Consultant shall not, either or alone or in association with
others, directly or indirectly provide services for other commercial entities that are not affiliated with MPM. 

  
 2 

 6. Inventions and Proprietary Information. 

6.1 Inventions. All inventions, discoveries, computer programs, data, technology, designs, innovations and improvements (whether or not
patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created, written, designed or developed by the Consultant, solely or jointly with others and whether during normal business hours or otherwise, if related
to the business of the Company (collectively, “Inventions”), shall be the sole property of the Company. Without limiting the generality of the foregoing, it is understood and agreed that “Inventions” shall include any of the
foregoing inventions, discoveries, computer programs, data, technology, designs, innovations and improvements that arise from the Consultant’s performance of services for the Company or from the use of the Company’s Proprietary
Information. The Consultant hereby assigns and agrees to assign to the Company all Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property rights and applications therefor, in
the United States and elsewhere and appoints any officer of the Company as his duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. Upon the request of the Company and at the
Company’s expense, the Consultant shall execute such further assignments, documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for,
obtaining and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention. The Consultant also hereby waives all claims to moral rights in any Inventions. 

6.2 Proprietary Information. 

(a) The Consultant acknowledges that his relationship with the Company is one of high trust and confidence and that in the course of his
service to the Company he will have access to and contact with Proprietary Information. The Consultant agrees that he will not, during the Consultation Period or at any time thereafter, disclose to others, or use for his benefit or the benefit of
others, any Proprietary Information or Invention. 
 (b) For purposes of this Agreement, Proprietary Information shall mean, by way of
illustration and not limitation, all information (whether or not patentable and whether or not copyrightable) owned, possessed or used by the Company, including, without limitation, any Invention, formula, vendor information, customer information,
apparatus, equipment, trade secret, process, research, report, technical data, know-how, computer program, software, software documentation, hardware design, technology, marketing or business plan, forecast,
unpublished financial statement, budget, license, price, cost and employee list that is communicated to, learned of, developed or otherwise acquired by the Consultant in the course of his service as a consultant to the Company. 

(c) The Consultant’s obligations under this Section 6.2 shall not apply to any information that (i) is or becomes known
to the general public under circumstances involving no breach by the Consultant or others of the terms of this Section 6.2, (ii) is generally disclosed to third parties by the Company without restriction on such third parties, or
(iii) is approved for release by written authorization of the Board of Directors of the Company. 
 (d) Upon termination of this
Agreement or at any other time upon request by the Company, the Consultant shall promptly deliver to the Company all records, files, memoranda, notes, designs, data, reports, price lists, customer lists, drawings, plans, computer programs, software,
software documentation, sketches, laboratory and research notebooks and other documents (and all copies or reproductions of such materials) relating to the business of the Company. 

  
 3 

 (e) The Consultant represents that his retention as a consultant with the Company and his
performance under this Agreement does not, and shall not, breach any agreement that obligates him to keep in confidence any trade secrets or confidential or proprietary information of his or of any other party or to refrain from competing, directly
or indirectly, with the business of any other party. The Consultant shall not disclose to the Company any trade secrets or confidential or proprietary information of any other party. 

6.3 Remedies. The Consultant acknowledges that any breach of the provisions of this Section 6 shall result in serious and
irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Consultant agrees, therefore, that, in addition to any other remedy it may have, the Company shall be entitled to enforce the
specific performance of this Agreement by the Consultant and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages. 

7. Defense and Indemnification. The Company agrees, at its sole expense, to defend Consultant against, and to indemnify and hold
Consultant harmless from, any liability, claim, judgment, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including without limitation reasonable attorneys’ fees and other costs and expenses of defense) relating
to a claim or suit by a third party against Consultant, either arising from this Agreement, the Consultant’s performance of services for the Company under this Agreement, or any Company products or services which result from the
Consultant’s performance of services under this Agreement. 
 8. Independent Contractor Status. The Consultant shall perform all
services under this Agreement as an “independent contractor” and not as an employee or agent of the Company. Consultant is free to determine the time and place of the Services to be provided under this Agreement. Consultant warrants to
perform his obligations under this Agreement with the usual standard of diligence but does not guarantee the achievement of any specific commercial objectives. The Consultant is not authorized to assume or create any obligation or responsibility,
express or implied, on behalf of, or in the name of, the Company or to bind the Company in any manner. 
 9. Notices. All notices
required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at
the address shown above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 9. 

10. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine
or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 

  
 4 

 11. Entire Agreement. This Agreement and the Stock Agreement constitute the entire
agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. 

12. Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Consultant.

 13. Governing Law. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the Commonwealth of
Massachusetts. 
 14. Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and
their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Consultant are personal and shall
not be assigned by him. 
 15. Miscellaneous. 

15.1 No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A
waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 

15.2 The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or
substance of any section of this Agreement. 
 15.3 In the event that any provision of this Agreement shall be invalid, illegal or otherwise
unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
set forth above. 
  

			
	TCR2, INC.
		
	By:	 	 /s/ Gregory Sieczkiewicz

	Name: Gregory Sieczkiewicz
	Title: Secretary
	
	CONSULTANT
	
	 /s/ Patrick Bauerle

	Patrick Baeuerle

  
 6 

 November 1, 2016 

Patrick Baeuerle, PhD 
 BY EMAIL 

Dear Patrick, 
 This letter serves to amend your Consulting
Agreement dated October 1, 2015 (the “Consulting Agreement”) with TCR2, Inc. (“TCR2”) in certain respects, as set
forth below. Capitalized terms used in this letter but not otherwise defined are as defined in the Consulting Agreement. Except as set forth below, the Consulting Agreement remains unmodified and in full force and effect. 

 

	 	•	 	 Your compensation under Section 2.1(a) of the Consulting Agreement will be revised to Euros 3,837.83 per
month, annualized to Euros 46,055.00. 

  

			
	Best,
	
	/s/ Garry Menzel
	
	Garry Menzel
	Chief Executive Officer

  

			
	AGREED AND ACCEPTED:
	
	 /s/ Patrick Bauerle

	Patrick Baeuerle, PhD

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]